340 related articles for article (PubMed ID: 9772061)
1. Multimodality treatment for gastric carcinoid tumor with liver metastases.
Caplin ME; Hodgson HJ; Dhillon AP; Begent R; Buscombe J; Dick R; Rolles K; Burroughs AK
Am J Gastroenterol; 1998 Oct; 93(10):1945-8. PubMed ID: 9772061
[TBL] [Abstract][Full Text] [Related]
2. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
3. [Individual therapeutic procedure in metastatic carcinoid of the small intestine].
Barthel A; Leonhardt U; Stöckmann F; Ramadori G
Leber Magen Darm; 1996 May; 26(3):164, 167-9. PubMed ID: 8709831
[TBL] [Abstract][Full Text] [Related]
4. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
5. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.
Claure RE; Drover DD; Haddow GR; Esquivel CO; Angst MS
Can J Anaesth; 2000 Apr; 47(4):334-7. PubMed ID: 10764178
[TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
7. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
8. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
9. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
Katakami N; Matsumoto H; Ishihara K; Umeda B
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
[TBL] [Abstract][Full Text] [Related]
11. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
12. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
[No Abstract] [Full Text] [Related]
13. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
14. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
Eriksson BK; Larsson EG; Skogseid BM; Löfberg AM; Lörelius LE; Oberg KE
Cancer; 1998 Dec; 83(11):2293-301. PubMed ID: 9840528
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome.
Majeed F; Porter TR; Tarantolo S; Duhachek-Stapelman A; Xie F; Elhendy A
Eur J Echocardiogr; 2007 Oct; 8(5):386-9. PubMed ID: 17011239
[TBL] [Abstract][Full Text] [Related]
16. Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature.
Spampatti MP; Massironi S; Rossi RE; Conte D; Sciola V; Ciafardini C; Ferrero S; Lodi L; Peracchi M
Eur J Gastroenterol Hepatol; 2012 May; 24(5):589-93. PubMed ID: 22465973
[TBL] [Abstract][Full Text] [Related]
17. Carcinoid tumour.
McStay MK; Caplin ME
Minerva Med; 2002 Oct; 93(5):389-401. PubMed ID: 12410171
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
19. [A case of multiple liver metastasis from ileac carcinoid effectively treated with continuous intraarterial infusion of somatostatin analog].
Wadamori K; Oka M; Shimizu R; Tangoku A; Hazama S; Yagyu T; Suzuki T; Hatano S; Kurokawa F; Okita K
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1669-72. PubMed ID: 7574789
[TBL] [Abstract][Full Text] [Related]
20. [Carcinoid tumors].
Tóth M; Prónai L; Németh AM; Tulassay Z
Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]